Jennifer T Chang, MD
Gastroenterology · Santa Clara
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Permanente Medical Group Inc · 10,928 clinicians in this group
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Chang’s office at (408) 851-1000 to ask if they take your plan before you enroll.
California Medical Board record
Licence A111788 · Current
Licensed to practise in California · since 2010 · expires 2028-04-30 · Columbia University College of Physicians and Surgeons.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Original Medicare doctor bills
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
Procedures Medicare counted
| Colonoscopy | 1-10 | None |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 1-10 | None |
Drugs they prescribed that Part D paid
$516,841
Pharmacies billed $516,841 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
599 generic and 164 brand-name prescriptions · $516,841 in drug cost · 33 antibiotic prescriptions to 20 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Stelara | 13 | $220,802 | $16,985 |
| Creon | 21 | $46,326 | $2,206 |
| Linzess | 19 | $26,079 | $1,373 |
| Mesalamine | 41 | $22,613 | $552 |
| Gavilyte-C | 222 | $5,238 | $24 |
See all 14 drugs
| Stelara | 13 | $220,802 | $16,985 |
| Creon | 21 | $46,326 | $2,206 |
| Linzess | 19 | $26,079 | $1,373 |
| Mesalamine | 41 | $22,613 | $552 |
| Gavilyte-C | 222 | $5,238 | $24 |
| Budesonide Dr | 39 | $3,374 | $87 |
| Pantoprazole | 109 | $1,613 | $15 |
| Cholestyramine | 28 | $1,425 | $51 |
| Lubiprostone | 15 | $1,324 | $88 |
| Diphenoxylate-Atropine | 13 | $392 | $30 |
| Dicyclomine | 12 | $294 | $24 |
| Nortriptyline | 12 | $198 | $16 |
| Prednisone | 19 | $191 | $10 |
| Omeprazole | 14 | $165 | $12 |
Year by year
| 2024 | 763 | 371 | None | 21% | $516,841 |
| 2023 | 658 | 357 | 0% (0) | 23% | $310,325 |
| 2022 | 593 | 397 | 0% (0) | 31% | $301,027 |
| 2021 | 655 | 366 | 0% (0) | 29% | $295,968 |
| 2020 | 421 | 239 | 0% (0) | None | $110,052 |
| 2019 | 477 | 338 | 0% (0) | 17% | $70,519 |
| 2018 | 721 | 553 | 0% (0) | 38% | $107,003 |
| 2017 | 483 | 350 | 0% (0) | 12% | $78,954 |
| 2016 | 317 | 225 | 0% (0) | 17% | $48,201 |
| 2015 | 54 | 50 | None | None | $5,050 |
| 2014 | 18 | 15 | None | None | $3,333 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 13 drugs
| Creon | 13 | $29,694 | $2,284 |
| Linzess | 23 | $26,542 | $1,154 |
| Motegrity | 14 | $23,699 | $1,693 |
| Lialda | 31 | $18,630 | $601 |
| Gavilyte-C | 221 | $4,590 | $21 |
| Budesonide Dr | 50 | $4,213 | $84 |
| Lubiprostone | 16 | $1,894 | $118 |
| Pantoprazole | 73 | $1,233 | $17 |
| Sucralfate | 16 | $1,151 | $72 |
| Cholestyramine | 16 | $915 | $57 |
| Lansoprazole | 12 | $412 | $34 |
| Famotidine | 13 | $181 | $14 |
| Prednisone | 13 | $142 | $11 |
2022: 9 drugs
| Stelara | 13 | $198,995 | $15,307 |
| Linzess | 15 | $23,709 | $1,581 |
| Lialda | 31 | $18,410 | $594 |
| Gavilyte-C | 218 | $3,526 | $16 |
| Budesonide Ec | 15 | $1,842 | $123 |
| Sucralfate | 19 | $1,627 | $86 |
| Peg-3350 and Electrolytes | 64 | $1,250 | $20 |
| Budesonide Dr | 13 | $1,222 | $94 |
| Pantoprazole | 59 | $1,051 | $18 |
2021: 10 drugs
| Linzess | 54 | $53,500 | $991 |
| Lialda | 33 | $24,138 | $731 |
| Budesonide Ec | 34 | $4,162 | $122 |
| Pantoprazole | 89 | $1,839 | $21 |
| Peg-3350 and Electrolytes | 88 | $1,836 | $21 |
| Gavilyte-C | 118 | $1,790 | $15 |
| Sucralfate | 12 | $960 | $80 |
| Peg 3350-Electrolyte | 18 | $486 | $27 |
| Prednisone | 18 | $381 | $21 |
| Ondansetron | 12 | $123 | $10 |
2020: 8 drugs
| Linzess | 52 | $33,823 | $650 |
| Mesalamine | 11 | $4,233 | $385 |
| Gavilyte-C | 114 | $2,179 | $19 |
| Budesonide Ec | 19 | $2,063 | $109 |
| Pantoprazole | 26 | $629 | $24 |
| Peg-3350 and Electrolytes | 21 | $449 | $21 |
| Gavilyte-G | 12 | $274 | $23 |
| Ondansetron | 11 | $164 | $15 |
2019: 6 drugs
| Lialda | 16 | $13,032 | $814 |
| Gavilyte-C | 253 | $9,115 | $36 |
| Linzess | 13 | $5,832 | $449 |
| Budesonide Ec | 17 | $1,797 | $106 |
| Pantoprazole | 41 | $1,205 | $29 |
| Omeprazole | 13 | $306 | $24 |
2018: 6 drugs
| Lialda | 23 | $28,630 | $1,245 |
| Creon | 15 | $18,607 | $1,240 |
| Gavilyte-C | 309 | $11,321 | $37 |
| Peg 3350-Electrolyte | 184 | $6,700 | $36 |
| Pantoprazole | 30 | $1,178 | $39 |
| Omeprazole | 19 | $453 | $24 |
2017: 5 drugs
| Lialda | 19 | $19,090 | $1,005 |
| Budesonide Ec | 12 | $13,743 | $1,145 |
| Gavilyte-C | 320 | $5,493 | $17 |
| Pantoprazole | 16 | $671 | $42 |
| Omeprazole | 22 | $614 | $28 |
2016: 3 drugs
| Carafate | 13 | $6,505 | $500 |
| Gavilyte-C | 180 | $3,084 | $17 |
| Omeprazole | 14 | $453 | $32 |
2015: 1 drug
| Gavilyte-C | 34 | $578 | $17 |
Money from drug and device companies
$25 in 2019
A payment is not proof that care is biased.
| E.R. Squibb & Sons L.L.C. | None | $25 | 1 payment
|
See the published payment
| E.R. Squibb & Sons L.L.C. | Meals · 2019-03-06 | None | $25 |
Professional record
- NPI
- 1598090441
- Licence
- CA A111788, NY 260153California A111788: Current · expires 2028-04-30
- Trained
- Columbia University College of Physicians and Surgeons, 2008
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Internal medicine (207R00000X)
- Mailing address
- 513 Parnassus Ave # 357, San Francisco, CA, 94143
- NPI first listed
- 2009-10-09
- NPI last updated
- 2022-02-11
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.